Edwards Lifesciences Corporation growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +13.8%
EBITDA: -21.5%
EBIT: +22.4%
EPS: -73.0%
Free cash flow: +66.8%
Operating cash flow: +55.1%

Forward estimates

Revenue: +10.7%
EBITDA: +53.1%
EPS: +64.9%

Three-year CAGR

Revenue: +4.1%
EBITDA: -10.0%
EBIT: -1.3%
Net income: -11.0%
EPS: -9.2%
Free cash flow: +11.9%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.